"KCNQ2 Potassium Channel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A very slow opening and closing voltage-gated potassium channel that is expressed in NEURONS and is commonly mutated in BENIGN FAMILIAL NEONATAL CONVULSIONS.
Descriptor ID |
D051658
|
MeSH Number(s) |
D12.776.157.530.400.600.900.124.249.750 D12.776.543.550.450.750.900.124.249.750 D12.776.543.585.400.750.900.124.249.750
|
Concept/Terms |
KCNQ2 Potassium Channel- KCNQ2 Potassium Channel
- Potassium Channel, KCNQ2
- Kv7.2 Potassium Channel
- Potassium Channel, Kv7.2
- Voltage-Gated K+ Channel KCNQ2
- Voltage Gated K+ Channel KCNQ2
- KCNQ2 Protein
|
Below are MeSH descriptors whose meaning is more general than "KCNQ2 Potassium Channel".
Below are MeSH descriptors whose meaning is more specific than "KCNQ2 Potassium Channel".
This graph shows the total number of publications written about "KCNQ2 Potassium Channel" by people in this website by year, and whether "KCNQ2 Potassium Channel" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2004 | 0 | 1 | 1 |
2005 | 1 | 0 | 1 |
2006 | 1 | 0 | 1 |
2008 | 2 | 0 | 2 |
2010 | 1 | 0 | 1 |
2014 | 3 | 0 | 3 |
2015 | 1 | 1 | 2 |
2016 | 1 | 1 | 2 |
2017 | 1 | 0 | 1 |
2018 | 1 | 0 | 1 |
2019 | 2 | 0 | 2 |
2021 | 2 | 0 | 2 |
2022 | 0 | 3 | 3 |
2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "KCNQ2 Potassium Channel" by people in Profiles.
-
Phenotypic and functional assessment of two novel KCNQ2 gain-of-function variants Y141N and G239S and effects of amitriptyline treatment. Neurotherapeutics. 2024 Jan; 21(1):e00296.
-
KCNQ2/3 Gain-of-Function Variants and Cell Excitability: Differential Effects in CA1 versus L2/3 Pyramidal Neurons. J Neurosci. 2023 09 20; 43(38):6479-6494.
-
KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism. EBioMedicine. 2022 Jul; 81:104130.
-
Removal of KCNQ2 from parvalbumin-expressing interneurons improves anti-seizure efficacy of retigabine. Exp Neurol. 2022 09; 355:114141.
-
High-throughput evaluation of epilepsy-associated KCNQ2 variants reveals functional and pharmacological heterogeneity. JCI Insight. 2022 03 08; 7(5).
-
Kcnq2/Kv7.2 controls the threshold and bi-hemispheric symmetry of cortical spreading depolarization. Brain. 2021 10 22; 144(9):2863-2878.
-
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. Am J Psychiatry. 2021 05 01; 178(5):437-446.
-
Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy. Epilepsia. 2019 09; 60(9):1870-1880.
-
Epileptic Encephalopathy In A Patient With A Novel Variant In The Kv7.2 S2 Transmembrane Segment: Clinical, Genetic, and Functional Features. Int J Mol Sci. 2019 Jul 10; 20(14).
-
Deletion of KCNQ2/3 potassium channels from PV+ interneurons leads to homeostatic potentiation of excitatory transmission. Elife. 2018 11 01; 7.